Add Yahoo as a preferred source to see more of our stories on Google. The rare neurogenetic disorder affects 1 in 15,000 people For the first time, Colin Farrell has opened up his home and talked ...

OV101 program in Angelman syndrome to pause pending full analysis of NEPTUNE trial and discussions with FDA Pivotal studies of OV935 (soticlestat) in Dravet syndrome and Lennox-Gastaut syndrome ...

ORLANDO, Fla.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, announced today that ...

Expansion Cohorts showed rapid, clinically meaningful improvement across multiple domains; improvements consistent or exceeding Dose-escalation Cohorts data at Day 170 Additional long-term data in ...

Add Yahoo as a preferred source to see more of our stories on Google. Award-winning actor Colin Farrell is creating a foundation to support people with intellectual disabilities and their families in ...

Please provide your email address to receive an email when new articles are posted on . DENVER — Treatment with a novel therapeutic led to clinically significant improvement in cognition for young ...

Ultragenyx (RARE) Pharmaceutical announced that the first patient has been dosed in the pivotal Phase 3 Aspire study, NCT06617429, evaluating the efficacy and safety of GTX-102, its investigational ...

Ultragenyx has found early success with its experimental treatment for the rare disease Angelman syndrome, supporting the company’s decision to acquire its development partner two years ago.

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (IONS) (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to ...

Affected populations: The disorder is believed to affect somewhere between 1 in 12,000 and 1 in 24,000 people, although these figures may be underestimated. Many cases of Angelman syndrome can go ...

Neurons with a fluorescent reporter for paternal UBE3A gene activity show only a background low fluorescent glow when treated with a vehicle control, but show a bright fluorescent glow when treated ...